Wyeth Taps Pharmacopeia Technology For Potential Small Molecule RA Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
The two firms will each develop and commercialize products resulting from research based on Pharmacopeia’s JAK3 inhibitor program.